HOME >> BIOLOGY >> NEWS
JCI Table of Contents, 1 October, 2003

A binding factor that exists and accumulates in the cytoplasm of resting cells. Relocation of NF-kappaB to the cell nucleus is a crucial step in the expression of many genes fundamental to cell development, survival, and function. Jean-Laurent Casanova and colleagues report a novel human mutation in the gene encoding the protein NEMO, which negatively regulates NF-kappaB activation. This mutation gives rise to the clinical syndrome ectodermal dysplasia, characterized by the abnormal development of the skin, hair, nails, teeth, and sweat glands in addition to an increased susceptibility to infection.

In an accompanying commentary, Jordan Orange and Raif Geha from Harvard Medical School discuss how the study of human gene mutations that result in dysreguation of the NF-kappaB pathway has provided insight into the functions of individual components of NF-kappaB activation, their interrelations, and the significance of these signaling pathways to the human body.

TITLE: A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency

AUTHOR CONTACT:
Jean-Laurent Casanova
Universit de Paris Ren Descartes-INSERM 550, Paris, France.
Phone: 33-1-40-61-53-81
Fax: 33-1-40-61-56-88
E-mail: casanova@necker.fr

View the PDF of this article at: https://www.the-jci.org/press/18714.pdf

ACCOMPANYING COMMENTARY:
Finding NEMO: genetic disorders of NF-kappaB activation

AUTHOR CONTACT:
Raif S. Geha
Children's Hospital, Boston, Massachusetts, USA.
Phone: 617-355-7603
Fax: 617-730-0528
E-mail: Raif.Geha@TCH.Harvard.edu

View the PDF of this commentary at: https://www.the-jci.org/press/19960.pdf



'"/>

Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
1-Oct-2003


Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology news :

1. JCI Table of Contents, 15 July 2004
2. JCI Table of Contents, January 15 2004
3. JCI Table of Contents, November 3, 2003
4. JCI Table of Contents, September 15, 2003
5. JCI Table of Contents
6. JCI Table of Contents, 15 August 2003
7. JCI Table of Contents, May 1, 2003
8. JCI Table of Contents, April 1, 2003
9. JCI Table of Contents, March 14, 2003
10. JCI Table of Contents, January 2, 2003
11. JCI Table of Contents, December 2, 2002

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
Breaking Biology News(10 mins):
(Date:2/21/2017)... , ... February 21, 2017 , ... ... organizations to build connected digital health applications, announced a partnership with Redox, a ... to seamlessly connect to many clinical systems while keeping data secure in the ...
(Date:2/21/2017)... ... February 21, 2017 , ... The medical potential of stem cells ... multiple areas of medicine, due to their differentiating characteristics. Stem cells are unique as ... ability to be induced to become tissue or organic-specific cells with special functions. ...
(Date:2/21/2017)... VANCOUVER, British Columbia , Feb. 21, 2017  OncoGenex ... apatorsen results from two randomized Phase 2 clinical trials were ... Genitourinary Cancers Symposium, held February 16 th - 18 th ... trials in bladder and prostate cancers demonstrated apatorsen was well-tolerated ... treatments. ...
(Date:2/21/2017)...   Invitae Corporation (NYSE: NVTA), one of ... members of the company,s management team will present at ... on Monday, March 6, 2017 at approximately 4:00 p.m. ... Massachusetts . The live, listen-only ... the investors section of the company,s website at ...
Breaking Biology Technology:
Cached News: